vTv Therapeutics (VTVT) Share-based Compensation (2015 - 2026)

vTv Therapeutics (VTVT) has 12 years of Share-based Compensation data on file, last reported at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 70.73% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $626000.0 (down 81.31% YoY), and the FY2025 full-year result was $51000.0, down 98.15% from the prior year.
• Share-based Compensation rose to $1.4 million in Q1 2026, from -$2.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $1.9 million in Q3 2024 to a low of -$2.7 million in Q4 2025.
• A 5-year average of $321647.1 and a median of $399000.0 in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation plunged 503.78% in 2023 and jumped 522.73% in 2025, its largest moves.
• Tracing VTVT's Share-based Compensation over 5 years: stood at $291000.0 in 2022, then sank by 503.78% to -$1.2 million in 2023, then soared by 170.21% to $825000.0 in 2024, then sank by 427.15% to -$2.7 million in 2025, then jumped by 151.43% to $1.4 million in 2026.
• Business Quant data shows VTVT's Share-based Compensation at $1.4 million in Q1 2026, -$2.7 million in Q4 2025, and $1.0 million in Q3 2025.